PubMed · 12042705
Ras processing as a therapeutic target in hematologic malignancies.
Abstract
Knowledge of signal transduction pathways has uncovered therapeutic targets for cancer. Based on genetic and biochemical studies of leukemia cells, inhibiting hyperactive Ras represents a rational therapeutic strategy for many hematologic malignancies. Because posttranslational processing by farnesyltransferase is essential for transformation by oncogenic Ras, specific inhibitors of this enzyme are being evaluated as cancer therapeutics. The authors review recent laboratory insights on farnesyltransferase biology and on the development of inhibitors, summarize preclinical and clinical data in myeloid malignancies, and briefly discuss other strategies of interfering with hyperactive Ras.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Doan Thuy Le, Kevin M Shannon. 2002. Ras processing as a therapeutic target in hematologic malignancies.. https://doi.org/10.1097/00062752-200207000-00008
Cite the original work for its findings. Save a collection to share your selection of sources.